BACKGROUND: Although there has been a dramatic increase in the accessibility and utilization of high-resolution MRI techniques for the evaluation of brain tumors, there is currently only a single report comparing stereotactic brain biopsy specimen to subsequent resection specimen exclusively in the management of gliomas. METHODS: The diagnoses in 43 cases of astrocytic brain tumors were derived using MRI-guided stereotactic biopsy followed by open resection of the lesion. The histologic diagnoses yielded by biopsy were compared with subsequent histologic diagnosis after open tumor resection. All biopsies and histologic diagnoses were made by the same surgeon and pathologist, respectively. RESULTS: In 23 patients undergoing resection <60 days after biopsy, the biopsy diagnosis was consistent with resection diagnosis in 18 cases (79%) and led to the correct treatment in 22 cases (96%). Recurrent glioblastoma multiforme (GBM) was undergraded as anaplastic astrocytoma in 4 patients. GBM was misdiagnosed as radiation necrosis in 1 patient. MR-nonenhancing lesions [10/10 (100%)] yielded histology that correlated with subsequent craniotomy, while only 8/13 (61%) MR-enhancing lesions yielded histology that was consistent with that at craniotomy (p < 0.05). In 20 patients undergoing resection because of radiologic tumor progression (mean 7 months after biopsy), 6/6 (100%) biopsy diagnoses of a specific glioma grade correlated with resection diagnosis, while only 6/14 (43%) biopsy diagnoses of radiation effect correlated with resection diagnosis (p < 0.01). CONCLUSION: MRI-guided stereotactic brain biopsy specimen accurately represents the grade of the larger glioma mass sufficiently to guide subsequent therapy. Enhancement on MR may be a negative prognostic indicator of biopsy accuracy.
BACKGROUND: Although there has been a dramatic increase in the accessibility and utilization of high-resolution MRI techniques for the evaluation of brain tumors, there is currently only a single report comparing stereotactic brain biopsy specimen to subsequent resection specimen exclusively in the management of gliomas. METHODS: The diagnoses in 43 cases of astrocytic brain tumors were derived using MRI-guided stereotactic biopsy followed by open resection of the lesion. The histologic diagnoses yielded by biopsy were compared with subsequent histologic diagnosis after open tumor resection. All biopsies and histologic diagnoses were made by the same surgeon and pathologist, respectively. RESULTS: In 23 patients undergoing resection <60 days after biopsy, the biopsy diagnosis was consistent with resection diagnosis in 18 cases (79%) and led to the correct treatment in 22 cases (96%). Recurrent glioblastoma multiforme (GBM) was undergraded as anaplastic astrocytoma in 4 patients. GBM was misdiagnosed as radiation necrosis in 1 patient. MR-nonenhancing lesions [10/10 (100%)] yielded histology that correlated with subsequent craniotomy, while only 8/13 (61%) MR-enhancing lesions yielded histology that was consistent with that at craniotomy (p < 0.05). In 20 patients undergoing resection because of radiologic tumor progression (mean 7 months after biopsy), 6/6 (100%) biopsy diagnoses of a specific glioma grade correlated with resection diagnosis, while only 6/14 (43%) biopsy diagnoses of radiation effect correlated with resection diagnosis (p < 0.01). CONCLUSION: MRI-guided stereotactic brain biopsy specimen accurately represents the grade of the larger glioma mass sufficiently to guide subsequent therapy. Enhancement on MR may be a negative prognostic indicator of biopsy accuracy.
Authors: Michail Plotkin; C Blechschmidt; G Auf; F Nyuyki; L Geworski; T Denecke; W Brenner; F Stockhammer Journal: Eur Radiol Date: 2010-06-03 Impact factor: 5.315
Authors: Maya Harary; Vasileios K Kavouridis; Matthew Torre; Hasan A Zaidi; Ugonma N Chukwueke; David A Reardon; Timothy R Smith; J Bryan Iorgulescu Journal: Neuro Oncol Date: 2020-03-05 Impact factor: 12.300
Authors: Laia Capdevila; Sara Cros; Jose-Luis Ramirez; Carolina Sanz; Cristina Carrato; Margarita Romeo; Olatz Etxaniz; Cristina Hostalot; Ana Massuet; Jose Luis Cuadra; Salvador Villà; Carmen Balañà Journal: J Neurooncol Date: 2014-01-07 Impact factor: 4.130
Authors: Brendan J McCullough; Valerie Ader; Brian Aguedan; Xu Feng; Daniel Susanto; Tara L Benkers; John W Henson; Marc Mayberg; Charles S Cobbs; Ryder P Gwinn; Stephen J Monteith; David W Newell; Johnny Delashaw; Sarah J Fouke; Steven Rostad; Bart P Keogh Journal: J Neurooncol Date: 2017-11-02 Impact factor: 4.130
Authors: Nader Pouratian; Melike Mut; Jay Jagannathan; M Beatriz Lopes; Mark E Shaffrey; David Schiff Journal: J Neurooncol Date: 2008-08-06 Impact factor: 4.130
Authors: Zezhong Ye; Richard L Price; Xiran Liu; Joshua Lin; Qingsong Yang; Peng Sun; Anthony T Wu; Liang Wang; Rowland H Han; Chunyu Song; Ruimeng Yang; Sam E Gary; Diane D Mao; Michael Wallendorf; Jian L Campian; Jr-Shin Li; Sonika Dahiya; Albert H Kim; Sheng-Kwei Song Journal: Clin Cancer Res Date: 2020-07-21 Impact factor: 12.531